|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility显示文摘Aromatase activity has commonly been associated with male infertility characterized by testicular dysfunction with low serum testosterone and/or testosterone to estradiol ratio.In this subset of patients,and particularly in those with hypogonadism,elevated levels of circulating estradiol may establish a negative feedback on the hypothalamic–pituitary–testicular axis by suppressing follicle-stimulating hormone(FSH)and luteinizing hormone(LH)production and impaired spermatogenesis.Hormonal manipulation via different agents such as selective estrogen modulators or aromatase inhibitors to increase endogenous testosterone production and improve spermatogenesis in the setting of infertility is an off-label option for treatment.We carried out a systematic review and meta-analysis of the literature of the past 30 years in order to evaluate the benefits of the use of aromatase inhibitors in the medical management of infertile/hypoandrogenic males.Overall,eight original articles were included and critically evaluated.Either steroidal(Testolactone)or nonsteroidal(Anastrozole and Letrozole)aromatase inhibitors were found to statistically improve all the evaluated hormonal and seminal outcomes with a safe tolerability profile.While the evidence is promising,future prospective randomized placebo-controlled multicenter trials are necessary to better define the efficacy of these medications. | Francesco Del Giudice Gian Maria Busetto Ettore De Berardinis Isabella Sperduti Matteo Ferro Martina Maggi Martin S Gross Alessandro Sciarra Michael L Eisenberg | 2020 | Asian Journal of Andrology2020，22，4： | 5 |
| 2 | CD44v6 Is a Marker of Constitutive and Reprogrammed Cancer Stem Cells Driving Colon Cancer Metastasis显示文摘 | Matilde Todaro Miriam Gaggianesi Veronica Catalano Antonina Benfante Flora Iovino Mauro Biffoni Tiziana Apuzzo Isabella Sperduti Silvia Volpe Gianfranco Cocorullo Gaspare Gulotta Francesco Dieli Ruggero De Maria Giorgio Stassi | 2014 | Cell Stem Cell2014，，3： | 3 |
| 3 | Metastatic pancreatic cancer: Is there a light at the end of the tunnel?显示文摘Due to extremely poor prognosis,pancreatic cancer(PDAC)represents the fourth leading cause of cancerrelated death in Western countries.For more than a decade,gemcitabine(Gem)has been the mainstay of first-line PDAC treatment.Many efforts aimed at improving single-agent Gem efficacy by either combining it with a second cytotoxic/molecularly targeted agent or pharmacokinetic modulation provided disappointing results.Recently,the field of systemic therapy of advanced PDAC is finally moving forward.Polychemotherapy has shown promise over single-agent Gem:regimens like PEFG-PEXG-PDXG and GTX provide significant potential advantages in terms of survival and/or disease control,although sometimes at the cost of poor tolerability.The PRODIGE 4/ACCORD 11 was the first phaseⅢtrial to provide unequivocal benefit using the polychemotherapy regimen FOLFIRINOX;however the less favorable safety profile and the characteristics of the enrolled population,restrict the use of FOLFIRINOX to young and fit PDAC patients.The nanoparticle albumin-bound paclitaxel(nab-Paclitaxel)formulation was developed to overcome resistance due to the desmoplastic stroma surrounding pancreatic cancer cells.Regardless of whether or not this is its main mechanisms of action,the combination of nabPaclitaxel plus Gem showed a statistically and clinically significant survival advantage over single agent Gem and significantly improved all the secondary endpoints.Furthermore,recent findings on maintenance therapy are opening up potential new avenues in the treatment of advanced PDAC,particularly in a new era in which highly effective first-line regimens allow patients to experience prolonged disease control.Here,we provide an overview of recent advances in the systemic treatment of advanced PDAC,mostly focusing on recent findings that have set new standards in metastatic disease.Potential avenues for further development in the metastatic setting and current efforts to integratenew effective chemotherapy regimens in earlier stages of disease(neoadjuvant,adjuvant,and multimodal approaches in both resectable and unresectable patients)are also briefly discussed. | Vanja Vaccaro Isabella Sperduti Sabrina Vari Emilio Bria Davide Melisi Carlo Garufi Carmen Nuzzo Aldo Scarpa Giampaolo Tortora Francesco Cognetti Michele Reni Michele Milella | 2015 | World Journal of Gastroenterology2015，21，16： | 2 |
| 4 | FOLFIRINOX versus gem- citabine for metastatic pancreatic cancer 显示文摘 | Vaccaro V Sperduti I Milella M | 2011 | N Engl J Med2011，365，8： | 1 |
| 5 | FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer显示文摘 | Vaccaro V Sperduti I Milella M | 2011 | N Engl J Med2011，365，8： | 1 |
| 6 | Identification of an adverse biologic profile in cyclophosphamide/metotrexate/5-Fluorouracil treated early stage breast bancer patients by Immunohisto chemical analysis of P13K/p-AktPathway alterations显示文摘 | Mottolese M Orlandi G Sperduti I | | 0，，24： | 1 |
| 7 | Recursive self-organizing network models显示文摘 | HAMMER B MICHELI A SPERDUTI A | 2004 | Neural Network2004，17，89： | 1 |
| 8 | The amygdala and the relevance detection theory of autism:an evolutionary perspective显示文摘 | Zalla T Sperduti M | 2013 | Front Hum Neurosci2013，7，： | 1 |
| 9 | FOLFIRINOX versus gem- citabine for metastatic pancreatic cancer 显示文摘 | Vaccaro V Sperduti I Milella M | 2011 | N Engl J Med2011，365，8： | 1 |
| 10 | HLA- A, -B, -C expression in colon carcinoma mimics that of the normal colonic mucosa and is prognostically relevant 显示文摘 | Benevolo Mafia Mottolese Marcella Piperno Giulia Sperduti | 2007 | Ame J Surg Pathol2007，31，1： | 1 |
| 11 | Biopathologic cha-racteristics re1ated to chromosome 11 aneusomy and cyclin D1 gene status in surgical1y resected stage I and Ⅱ breast cancer:Identification of an adverse prognostic profile显示文摘 | Mottolese M 0rlandi G Sperduti I | | 0，，02： | 1 |
| 12 | Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile显示文摘 | Mottolese M Orlandi G Sperduti I | 2007 | Am J Surg Pathol2007，31，2： | 1 |
| 13 | A general framework for unsupervised processing of structured data 显示文摘 | Hammer B Mieheli A Sperduti A | 2004 | Neuro Computing2004，57，： | 1 |
| 14 | Symptom and joint mobility pro- gression in the joint hypermobility syndrome ( Ehlers-Danlos syndrome, hypermobility type) 显示文摘 | Castori M Sperduti I Celletti C | 2011 | Clin Exp Rheumatol2011，29，6： | 1 |
| 15 | A self-organizing map for adaptive processing of structured data 显示文摘 | Hagenbuchner M Sperduti A Tsoi A C | 2003 | IEEE Transactions on Neural Networks2003，14，3： | 1 |
| 16 | Sun protec-tion among Spanish beachgoers : knowledge, attitudeand behaviour显示文摘 | Cercato MC Ramazzotti V Sperduti I | 2015 | J Cancer Educ2015，30，1： | 1 |
| 17 | Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage Ⅰ and Ⅱ breast cancer: Identification of an adverse prognostic profile显示文摘 | Mottolese M Orlandi G Sperduti I | 2007 | Am J Surg Pathol2007，31，2： | 1 |
| 18 | A re-weighting strategy for improving margins显示文摘 | Aiolli F Sperduti A | 2002 | Artifieal Intelligence2002，1，37： | 1 |
| 19 | Multiclass Classification with Multi-Prototype Support Vector Machines显示文摘 | Fabio Aio1li Alessandro Sperduti | 2005 | Journal of Machine Learning Research2005，，： | 1 |
| 20 | Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer显示文摘 | E. Bria P. Visca F. Novelli B. Casini M.G. Diodoro R. Perrone-Donnorso C. Botti I. Sperduti F. Facciolo M. Milella F.L. Cecere F. Cognetti M. Mottolese | 2007 | European Journal of Surgical Oncology2007，，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员